Holoclar

(Autologous human corneal epithelial cells)

• 300,000-1.2million cells/3.8square cm living tissue equivalent

Notes

1. NICE TA467: Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) is recommended as an option in people with moderate to severe limbal stem cell deficiency after eye burns, only if the criteria specified in NICE TA467 are met (August 2017).

Tebentafusp

• Solution for infusion vials 100micrograms/0.5ml

Notes

1. NICE TA1027: Tebentafusp (Kimmtrak) is recommended, within its marketing authorisation, for treating HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults, only recommended if the company provides it according to the commercial arrangement (January 2025).

Voretigene neparvovec

• Concentrate and solvent for solution for injection 5 x 10¹² vg/ml

Notes

1. NICE HST11: Voretigene neparvovec (Luxturna) is recommended, within its marketing authorisation, as an option for treating RPE65-mediated inherited retinal dystrophies in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells, and only if the company provides it according to the commercial arrangement (October 2019).